Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

Las legislaturas publican los títulos, el historial y el texto oficial de los proyectos de ley en inglés, y los resúmenes provienen de fuentes en inglés, por eso aquí aparecen en inglés.

H.R. 8205119.º Congreso

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Leer el proyecto completo

Avance

  1. Presentado
  2. En comité
  3. Aprobado por la Cámara
  4. Aprobado por el Congreso
  5. Enviado al presidente
  6. Se convirtió en ley

En lenguaje sencillo

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The act reauthorizes

  • grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
  • grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
  • a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. 

Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.

Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Resumen del Servicio de Investigación del Congreso (CRS), una oficina no partidista de la Biblioteca del Congreso. Versión resumida: Public Law.

Historial legislativo

  1. Became Public Law No: 119-138.

  2. Signed by President.

  3. Presented to President.

  4. Senado

    Message on Senate action sent to the House.

  5. Senado

    Passed Senate without amendment by Voice Vote. (consideration: CR S5120)

  6. Senado

    Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)

  7. Senado

    Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.

  8. Cámara de Representantes

    Motion to reconsider laid on the table Agreed to without objection.

  9. Cámara de Representantes

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

  10. Cámara de Representantes

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

  11. Cámara de Representantes

    Considered as unfinished business. (consideration: CR H5159)

  12. Cámara de Representantes

    At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.

  13. Cámara de Representantes

    DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.

  14. Cámara de Representantes

    Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)

  15. Cámara de Representantes

    Mr. Guthrie moved to suspend the rules and pass the bill, as amended.

  16. Cámara de Representantes

    Placed on the Union Calendar, Calendar No. 637.

  17. Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

  18. Cámara de Representantes

    Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.

  19. Cámara de Representantes

    Committee Consideration and Mark-up Session Held

  20. Cámara de Representantes

    Forwarded by Subcommittee to Full Committee by Voice Vote.

  21. Cámara de Representantes

    Subcommittee Consideration and Mark-up Session Held

  22. Cámara de Representantes

    Referred to the Subcommittee on Health.

  23. Cámara de Representantes

    Referred to the House Committee on Energy and Commerce.

  24. Introduced in House